open access

Vol 2, No 3 (2017)
CASE REPORTS
Published online: 2017-12-28
Get Citation

Diagnosis and management of a patient with idiopathic macular telangiectasia type 2

Ioannis Mallias, Panagiota Mylova, Anastasia Tassiopoulou
DOI: 10.5603/OJ.2017.0018
·
Ophthalmology J 2017;2(3):83-86.

open access

Vol 2, No 3 (2017)
CASE REPORTS
Published online: 2017-12-28

Abstract

This is a case report discussing the case of a patient with idiopathic macular telangiectasia type 2. The diagnosis and the management of the patient are analysed as well as the possible factors that attribute to the appearance of idiopathic macular telangiectasia.

Abstract

This is a case report discussing the case of a patient with idiopathic macular telangiectasia type 2. The diagnosis and the management of the patient are analysed as well as the possible factors that attribute to the appearance of idiopathic macular telangiectasia.
Get Citation

Keywords

MacTel, MacTel 2, macular telangiectasia type 2

About this article
Title

Diagnosis and management of a patient with idiopathic macular telangiectasia type 2

Journal

Ophthalmology Journal

Issue

Vol 2, No 3 (2017)

Pages

83-86

Published online

2017-12-28

DOI

10.5603/OJ.2017.0018

Bibliographic record

Ophthalmology J 2017;2(3):83-86.

Keywords

MacTel
MacTel 2
macular telangiectasia type 2

Authors

Ioannis Mallias
Panagiota Mylova
Anastasia Tassiopoulou

References (18)
  1. Wu L, Evans T, Arevalo JF. Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2). Surv Ophthalmol. 2013; 58(6): 536–559.
  2. Clemons TE, Gillies MC, Chew EY, et al. Macular Telangiectasia Project Research Group. Medical characteristics of patients with macular telangiectasia type 2 (MacTel Type 2) MacTel project report no. 3. Ophthalmic Epidemiol. 2013; 20(2): 109–113.
  3. Sallo FB, Leung I, Zeimer M, et al. MacTel Study Group. Abnormal retinal reflectivity to short-wavelength light in type 2 idiopathic macular telangiectasia. Retina. 2017 [Epub ahead of print].
  4. Heeren TFC, Clemons T, Scholl HPN, et al. Progression of vision loss in macular telangiectasia type 2. Invest Ophthalmol Vis Sci. 2015; 56(6): 3905–3912.
  5. Sallo FB, Leung I, Clemons TE, et al. MacTel CNTF Research Group. Correlation of structural and functional outcome measures in a phase one trial of ciliary neurotrophic factor in type 2 idiopathic macular telangiectasia. Retina. 2017 [Epub ahead of print].
  6. Gonzalez MA, Shechtman D, Haynie JM, et al. Unveiling idiopathic macular telangiectasia: clinical applications of optical coherence tomography angiography. Eur J Ophthalmol. 2017; 27(4): e129–e133.
  7. Chidambara L, Gadde SGK, Yadav NK, et al. Characteristics and quantification of vascular changes in macular telangiectasia type 2 on optical coherence tomography angiography. Br J Ophthalmol. 2016; 100(11): 1482–1488.
  8. Toto L, Di Antonio L, Mastropasqua R, et al. Multimodal imaging of macular telangiectasia type 2: Focus on vascular changes using optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2016; 57(9): OCT268–OCT276.
  9. Alkin Z, Yilmaz I, Ozkaya A, et al. Anti-vascular endothelial growth factor treatment for proliferative macular telangiectasia type 2. Middle East Afr J Ophthalmol. 2016; 23(2): 222–224.
  10. Chhablani J, Dedhia CJ, Peguda HK, et al. Short-term safety of 2 mg intravitreal ziv-aflibercept. Retina. 2017; 37(10): 1859–1865.
  11. Aydoğan T, Erdoğan G, Ünlü C, et al. Intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia. Turk J Ophthalmol. 2016; 46(6): 270–273.
  12. Toygar O, Guess MG, Youssef DS, et al. Long-term outcomes of intravitreal bevacizumab therapy for subretinal neovascularization secondary to idiopathic macular telangiectasia type 2. Retina. 2016; 36(11): 2150–2157.
  13. Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol. 1982; 100(5): 769–780.
  14. Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993; 100(10): 1536–1546.
  15. Gamulescu MA, Walter A, Sachs H, et al. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2008; 246(8): 1189–1193.
  16. Charbel Issa P, Finger RP, Kruse K, et al. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol. 2011; 151(5): 876–886.e1.
  17. Wilson C. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Archives of Ophthalmology. 1992; 110(8): 1155.
  18. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 2005; 80(2): 249–258.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, 73 Świętokrzyska St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl